Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673.

Cancer immunotherapy comes of age.

Author information

  • 1Genentech, 1 DNA Way, South San Francisco, California 94080, USA. mellman.ira@gene.com

Abstract

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

PMID:
22193102
[PubMed - indexed for MEDLINE]
PMCID:
PMC3967235
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk